Tech

FDA blocks review of Moderna's mRNA-1010 flu shot

The FDA has refused to initiate a formal review of Moderna's experimental flu vaccine, mRNA-1010, signaling a regulatory setback for the program. The agency cited trial comparator design concerns—rather than safety or efficacy issues—as the reason for the pause.

📅 February 10, 2026
⏱️ 2 min read
FDA blocks review of Moderna's mRNA-1010 flu shot

Key Takeaways

  • FDA declined to start formal review of mRNA-1010 due to comparator-design concerns
  • Moderna disputes the comparator rationale and says rules don’t require using the most advanced vaccine as comparator
  • Moderna requested a meeting with the FDA to discuss next steps; no safety/efficacy issues were identified
  • Stock fell about 7% in after-hours trading as investors priced in regulatory risk

People Involved

  • Stéphane BancelCEO, Moderna
  • Peter MarksDirector, FDA Center for Biologics Evaluation and Research (CBER)

Entities Involved

  • Moderna, Inc. (MRNA)Biotech company developing mRNA vaccines
  • U.S. Food and Drug Administration (FDA)Regulatory agency reviewing the submission

MarketMoodz Analysis

The regulatory setback shifts focus from mRNA-1010's data quality to the process by which vaccines are evaluated. With no safety or efficacy red flags cited, the pause delays potential revenue and timeline expectations for Moderna's influenza/COVID-19 vaccine strategy while Moderna and the FDA renegotiate next steps.

Context around vaccine regulation has tightened amid political scrutiny, which could influence how trial design and comparator choices are evaluated in future submissions. The effect may ripple beyond Moderna, shaping investor expectations for peers facing similar regulatory scrutiny.

Looking ahead, Moderna’s next move—holding a formal meeting with the FDA to outline a path forward—will be critical. Any pathway could involve trial redesign, alternative comparators, or adjusted endpoints, with implications for the timing of possible approvals and long-term earnings.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial